Clinical Trial Update: Observational Prospective Study OPTIMA II - Follow-up

View source ↗

Summary

A completed observational follow-up study OPTIMA II, sponsored by AstraZeneca, evaluating major adverse cardiovascular and cerebrovascular events (MACCE).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Cerebrovascular Disease

Snippet

Sponsor: AstraZeneca | Conditions: Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) | Status: COMPLETED